CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin

SIMPLE SUMMARY: Roughly 85–90% of adult and pediatric acute myeloid leukemia (AML) are CD33-positive. Gemtuzumab ozogamicin (GO), a humanized murine IgG4 anti-CD33 antibody, is the first target therapy approved in AML therapeutic scenario. This review focuses on current biological information and cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Molica, Matteo, Perrone, Salvatore, Mazzone, Carla, Niscola, Pasquale, Cesini, Laura, Abruzzese, Elisabetta, de Fabritiis, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268215/
https://www.ncbi.nlm.nih.gov/pubmed/34203180
http://dx.doi.org/10.3390/cancers13133214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268215/
https://www.ncbi.nlm.nih.gov/pubmed/34203180
http://dx.doi.org/10.3390/cancers13133214

Ejemplares similares